OMISIRGE (omidubicel-onlv)
HEMATOPOIETIC AGENTS - HEMATOPOIETIC GENE THERAPY AGENTS·ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT NEUTROPHIL RECOVERY
GAMIDA CELL, IN
Indication
Allogeneic hematopoietic stem cell transplant neutrophil recovery
Allogeneic hematopoietic stem cell transplant neutrophil recovery describes a critical hematologic milestone and therapeutic objective following conditioning therapy and donor stem cell infusion in recipients treated for hematologic malignancies or bone marrow disorders. Read more about Allogeneic hematopoietic stem cell transplant neutrophil recovery
1 drugs 1 manufacturers
Drugs that treat it
Common Allogeneic hematopoietic stem cell transplant neutrophil recovery therapies.
Filter & compare in the drug finder →Opens the drug finder with Allogeneic hematopoietic stem cell transplant neutrophil recovery preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAllogeneic hematopoietic stem cell transplant neutrophil recovery describes a critical hematologic milestone and therapeutic objective following conditioning therapy and donor stem cell infusion in recipients treated for hematologic malignancies or bone marrow disorders.
Rather than representing an independent disease, it denotes the clinical state of donor myeloid engraftment, characterized by the successful homing, proliferation, and differentiation of donor progenitor cells within the recipient bone marrow microenvironment.
Clinically defined as achieving an absolute neutrophil count of at least 500 cells per microliter across consecutive days, this recovery resolves the profound, post-transplant neutropenia that exposes patients to life-threatening bacterial and opportunistic infections.
Accelerating or supporting this milestone is a primary regulatory and therapeutic aim intended to shorten the duration of severe immunodeficiency and decrease transplant-related infectious complications.
- europeanpharmaceuticalreview.com
Allogeneic hematopoietic stem cell transplant neutrophil recovery describes a critical hematologic milestone and therapeutic objective following conditioning therapy and donor stem cell infusion in recipients treated for hematologic malignancies or bone marrow disorders Accelerating or supporting this milestone is a primary regulatory and therapeutic aim intended to shorten the duration of severe immunodeficiency and decrease transplant-related infectious complications
- uhcprovider.com
Allogeneic hematopoietic stem cell transplant neutrophil recovery describes a critical hematologic milestone and therapeutic objective following conditioning therapy and donor stem cell infusion in recipients treated for hematologic malignancies or bone marrow disorders Clinically defined as achieving an absolute neutrophil count of at least 500 cells per microliter across consecutive days, this recovery resolves the profound, post-transplant neutropenia that exposes patients to life-threatening...
- cancer.gov
Allogeneic hematopoietic stem cell transplant neutrophil recovery describes a critical hematologic milestone and therapeutic objective following conditioning therapy and donor stem cell infusion in recipients treated for hematologic malignancies or bone marrow disorders
- nmdp.org
Rather than representing an independent disease, it denotes the clinical state of donor myeloid engraftment, characterized by the successful homing, proliferation, and differentiation of donor progenitor cells within the recipient bone marrow microenvironment Clinically defined as achieving an absolute neutrophil count of at least 500 cells per microliter across consecutive days, this recovery resolves the profound, post-transplant neutropenia that exposes patients to life-threatening bacterial ...
- transplants.org
Rather than representing an independent disease, it denotes the clinical state of donor myeloid engraftment, characterized by the successful homing, proliferation, and differentiation of donor progenitor cells within the recipient bone marrow microenvironment
- acibademinternational.com
Clinically defined as achieving an absolute neutrophil count of at least 500 cells per microliter across consecutive days, this recovery resolves the profound, post-transplant neutropenia that exposes patients to life-threatening bacterial and opportunistic infections
- pahealthwellness.com
Accelerating or supporting this milestone is a primary regulatory and therapeutic aim intended to shorten the duration of severe immunodeficiency and decrease transplant-related infectious complications
Personalize your experience
Follow Allogeneic hematopoietic stem cell transplant neutrophil recovery and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.